Provided by Tiger Trade Technology Pte. Ltd.

Amneal Pharmaceuticals, Inc.

19.65
0.0000
Pre-market: 19.61-0.0400-0.20%04:01 EDT
Volume:3.24M
Turnover:62.95M
Market Cap:6.27B
PE:40.87
High:19.72
Open:19.65
Low:18.97
Close:19.65
52wk High:21.18
52wk Low:9.56
Shares:319.00M
Float Shares:191.00M
Volume Ratio:0.86
T/O Rate:1.70%
Dividend:- -
Dividend Rate:- -
EPS(TTM):0.4808
EPS(LYR):0.2200
ROE:613.02%
ROA:8.60%
PB:189.81
PE(LYR):89.32

Loading ...

Amneal Gains After Slightly Lifting Full-year Forecast, Q2 Beat

Reuters
·
Jul 30

Stock Track | Amneal Pharmaceuticals Soars 9.95% in Pre-market After Q2 Earnings Beat and Raised Guidance

Stock Track
·
Jul 30

Amneal Q2 Revenue Beats on Specialty Segment Growth

Reuters
·
Jul 30

GUIDANCE: (AMRX) Amneal Pharmaceuticals Expects Full Year 2026 Revenue Range $3.10B - $3.20B, vs. FactSet Est of $3.11B

MT Newswires Live
·
Jul 30

Amneal Q2 FY26 GAAP Net Income More than Doubles to $58 Million; Revenue Rises 10% to $796 Million

Reuters
·
Jul 30

Amneal Pharmaceuticals Shares up 10.5% Premarket After Q2 Profit Beat

THOMSON REUTERS
·
Jul 30

Amneal Pharmaceuticals Q2 Revenue USD 796 Million

Reuters
·
Jul 30

Amneal Pharmaceuticals Q2 Adj. EPS $0.30 Beats $0.22 Estimate, Sales $796.197M Beat $768.206M Estimate

Benzinga Earnings
·
Jul 30

Amneal Pharmaceuticals Outlook FY Adjusted EPS USD 0.96-1.06

THOMSON REUTERS
·
Jul 30

Amneal Pharmaceuticals Q2 Adjusted EPS USD 0.3 VS. Ibes Estimate USD 0.22

THOMSON REUTERS
·
Jul 30

Amneal Pharmaceuticals Outlook FY Revenue USD 3,100-3,200 Million

THOMSON REUTERS
·
Jul 30

Amneal Pharmaceuticals Outlook FY Capex USD 150 Million

THOMSON REUTERS
·
Jul 30

Amneal Reports Second Quarter 2026 Financial Results

THOMSON REUTERS
·
Jul 30

Goldman Sachs Reaffirms Their Buy Rating on Amneal Pharmaceuticals (AMRX)

TIPRANKS
·
Jul 27

Earning Preview: Amneal Pharmaceuticals, Inc. this quarter’s revenue is expected to increase by 3.18%, and institutional views are bullish

Earnings Agent
·
Jul 24

Analysts Have Conflicting Sentiments on These Healthcare Companies: Trevi Therapeutics (TRVI), Amneal Pharmaceuticals (AMRX) and Erasca (ERAS)

TIPRANKS
·
Jul 20

Amneal receives FDA approval for additional iohexol strengths, presentations

TIPRANKS
·
Jul 17

Amneal Wins FDA Approval for Additional Iohexol Injection Strengths and Vial Sizes

Reuters
·
Jul 17

Amneal Pharma - to Launch New Iohexol Injection Products in Q3 2026

THOMSON REUTERS
·
Jul 17

Amneal Expands Iohexol Injection Portfolio with U.S. FDA Approval of Additional Strengths and Presentations

THOMSON REUTERS
·
Jul 17